UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 0701.187C

Total Pages in this Submission

TO THE COMMISSIONER FOR PATENTS

P.O. Box 1450 Alexandria, VA 22313-1450
Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an
CARBONATE AND CARBAMATE MODIFIED FORMS OF CLUCOCORTICOUS IN COMPUNATION WITH
B2 ADRENERGIC AGONISTS
and invented by:
Mark G. Currie; Steve Jones; Paul Grover and Chris H. Senanayake
Fo CONTINUATION ADDITION
If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information: ☐ Continuation ☐ Divisional ☒ Continuation-in-part (CIP) of prior application No. 10/369 828
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: 10/369,828 Which is a:
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:
Which is a:
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:
Enclosed are:
Application Elements
1. Filing fee as calculated and transmitted as described below
2. Specification having pages and including the following:
a. 🗵 Descriptive Title of the Invention
b. 🗵 Cross References to Related Applications (if applicable)
c. Statement Regarding Federally-sponsored Research/Development (if applicable)
d. Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix
e. 🗵 Background of the Invention
f. 🗵 Brief Summary of the Invention
g. 🗵 Brief Description of the Drawings (if filed)
h. 🗵 Detailed Description
i. 🗵 Claim(s) as Classified Below
j. 🗵 Abstract of the Disclosure

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 0701.187C

Total Pages in this Submission

Application Elements (Continued)

3.	X	Drawing(s) (when necessary as prescribed by 35 USC 113)							
	a.	☑ Formal Number of Sheets 3							
	b.	☐ Informal Number of Sheets							
4.	X	Oath or Declaration							
	a.	☐ Newly executed (original or copy) ☑ Unexecuted							
	b.	☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)							
	c.	☐ With Power of Attorney ☐ Without Power of Attorney							
	d. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).								
5.		Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.							
6.		CD ROM or CD-R in duplicate, large table or Computer Program (Appendix)							
7.	X	Application Data Sheet (See 37 CFR 1.76)							
8.		Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)							
	a.	☐ Computer Readable Form (CRF)							
	b.	☐ Specification Sequence Listing on:							
		i. CD-ROM or CD-R (2 copies); or							
•		ii. 🗖 Paper							
	C.	Statement(s) Verifying Identical Paper and Computer Readable Copy							
		Accompanying Application Parts							
9.		Assignment Papers (cover sheet & document(s))							
10.		37 CFR 3.73(B) Statement (when there is an assignee)							
11.		English Translation Document (if applicable)							
12.	X	Information Disclosure Statement/PTO-1449 Copies of IDS Citations							
13.		Preliminary Amendment							
14.	X	Return Receipt Postcard (MPEP 503) (Should be specifically itemized)							
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)							
16.	X	Certificate of Mailing							
		☐ First Class ☒ Express Mail (Specify Label No.): EV 185212712 US							

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 0701.187C

Total Pages in this Submission

Additional Enclosure	Additional Enclosures (please identify below):							
	•	·						

Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)

18. Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

Warning

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 0701.187C

Total Pages in this Submission

Fee Calculation and Transmittal

		CLAIMS A	AS FILED			
For	#Filed	#Allowed	#Extra		Rate	Fee
Total Claims	25	- 20 =	5	x	\$18.00	\$90.00
Indep. Claims	4	- 3 =	1	x	\$84.00	\$84.00
Multiple Dependen	t Claims (check	if applicable)				\$0.00
		•			BASIC FEE	\$750.00
OTHER FEE (spec	ify purpose)				·	\$0.00
				·	TOTAL FILING FEE	\$924.00
⊠ Credit a ⊠ Charge		t. Iling fees required		.F.R. 1.1	l6 and 1.17. ne Notice of Allowance,	
pursual	nt to 37 C.F.R. 1	.311(b).		Mar	the Boline Signature	
Dated: August 1, 2	003				. Boden, Esq. Reg. No. 3 for Applicants	39,115
			5	5 Columb	othenberg Farley & Mesiti P via Circle	P.C.
cc:	•		4	Albany, NY 12203		

Phone: 518-452-5600 Fax: 518-452-5579

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Applicant: Currie et. al.

Title: CARBONATE AND CARBAMATE MODIFIED FORMS OF GLUCOCORTICOIDS

IN COMBINATION WITH β2 ADRENERGIC AGONISTS

Attorney Docket No.: 0701.187c

"EXPRESS MAIL" Mailing Label No.: EV 185212712 US

Date of Deposit: August 1, 2003

Enclosed are:

* Express Mail Certificate - Label No.: EV 185212712 US

* One (1) Acknowledgment Postcard

- * Check for \$924.00 (Patent Application filing fee) (Large Entity)
- * Utility Patent Application Transmittal (4 pages) (in duplicate)
- * Patent Application (30 pages)
- * Formal Drawings (3 sheets)
- * Unexecuted Declaration and Power of Attorney for Patent Application (4 pages)
- * Application Data Sheet (2 pages)
- * Information Disclosure Statement (with 8 references)

37 CFR 1.10 Certification

I hereby certify that this paper and the indicated enclosures are being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and addressed to:

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Christine Adkins

(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)